My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 652

    1.

    Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.

    Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR.

    Diabetes. 2005 Aug;54(8):2436-46.PMID: 16046312 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

    Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR.

    Diabetologia. 2007 Jul;50(7):1532-40. Epub 2007 May 8.PMID: 17486314 [PubMed - indexed for MEDLINE]Related articles

    3.

    Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

    Parker JC, Irwin N, Lavery KS, Green BD, O'Harte FP, Gault VA, Flatt PR.

    Biol Chem. 2007 Feb;388(2):221-6.PMID: 17261085 [PubMed - indexed for MEDLINE]Related articles

    4.

    Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

    Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR.

    Diabetologia. 2007 Aug;50(8):1752-62. Epub 2007 Jun 9.PMID: 17558485 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.

    Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P, O'Harte FP, Flatt PR.

    Biol Chem. 2004 Sep;385(9):845-52.PMID: 15493880 [PubMed - indexed for MEDLINE]Related articles

    6.

    Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.

    McClean PL, Gault VA, Irwin N, McCluskey JT, Flatt PR.

    Diabetes Obes Metab. 2008 Apr;10(4):336-42.PMID: 18333892 [PubMed - indexed for MEDLINE]Related articles

    7.

    Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.

    Irwin N, Hunter K, Flatt PR.

    Peptides. 2008 Jun;29(6):1036-41. Epub 2008 Jan 18.PMID: 18291559 [PubMed - indexed for MEDLINE]Related articles

    8.

    Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.

    Gault VA, Hunter K, Irwin N, Greer B, Green BD, Harriott P, O'Harte FP, Flatt PR.

    Biol Chem. 2007 Feb;388(2):173-9.PMID: 17261080 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.

    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.

    J Endocrinol. 2006 Oct;191(1):93-100.PMID: 17065392 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).

    Irwin N, Green BD, Parker JC, Gault VA, O'Harte FP, Flatt PR.

    Regul Pept. 2006 Jul 15;135(1-2):45-53. Epub 2006 May 3.PMID: 16675042 [PubMed - indexed for MEDLINE]Related articles

    11.

    GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.

    McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR.

    Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1746-55. Epub 2007 Sep 11.PMID: 17848629 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.

    Irwin N, Hunter K, Flatt PR.

    Peptides. 2007 Nov;28(11):2192-8. Epub 2007 Aug 19.PMID: 17884253 [PubMed - indexed for MEDLINE]Related articles

    13.

    Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

    O'Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR.

    Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1674-82. Epub 2007 Feb 13.PMID: 17299087 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

    Irwin N, Green BD, Mooney MH, Greer B, Harriott P, Bailey CJ, Gault VA, O'Harte FP, Flatt PR.

    J Pharmacol Exp Ther. 2005 Sep;314(3):1187-94. Epub 2005 May 27.PMID: 15923344 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

    McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR.

    Br J Pharmacol. 2008 Nov;155(5):690-701. Epub 2008 Aug 11.PMID: 18695644 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?

    Flatt PR.

    Diabet Med. 2008 Jul;25(7):759-64.PMID: 18513308 [PubMed - indexed for MEDLINE]Related articles

    17.

    Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

    Irwin N, Clarke GC, Green BD, Greer B, Harriott P, Gault VA, O'Harte FP, Flatt PR.

    Biochem Pharmacol. 2006 Sep 14;72(6):719-28. Epub 2006 Jul 20.PMID: 16859646 [PubMed - indexed for MEDLINE]Related articles

    18.

    Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.

    J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. Epub 2006 Apr 28.PMID: 16648370 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.

    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.

    Diabetologia. 2003 Feb;46(2):222-30. Epub 2003 Feb 12.PMID: 12627321 [PubMed - indexed for MEDLINE]Related articles

    20.

    Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.

    Irwin N, McClean PL, Patterson S, Hunter K, Flatt PR.

    Biol Chem. 2009 Jan;390(1):75-80.PMID: 18937625 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity